Vaccine and Monoclonal Antibody Studies in HIV-infected Subjects
$531,136ZIAFY2013AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications & trials
Paper 38587079Paper 35411076Paper 34213402Paper 34166231Paper 33730454Paper 33587510Paper 33587505Paper 33493795Paper 32866318Paper 31272988Paper 31000477Paper 30364428Paper 27959728Paper 26702094Paper 25142607Paper 23482645Paper 20479938
Abstract
Summary: This clinical research project is for clinical trials related to active immunity (vaccines) and passive immunity (monoclonal antibodies) directed against HIV that are evaluated in HIV-infected volunteers through clinical trials conducted by the VRC Clinic at the NIH Clinical Center. A brief summary of each study to date follows. VRC 101 (06-I-0056) was the first Phase I therapeutic study of two candidate HIV-1 vaccines developed by the VRC and administered in a prime-boost regimen. VRC 601 (13-I-0189) is the first Phase I dose-escalation study in HIV-infected volunteers of a human monoclonal antibody developed by the VRC with broad HIV-1 neutralizing activity.
View original record on NIH RePORTER →